{"name":"Tyme Technologies","slug":"tyme","ticker":"TYME","exchange":"NASDAQ","domain":"tfrmpharma.com","description":"Tyme Technologies is a biopharmaceutical company focused on developing innovative cancer therapies. The company's lead product, SM88, is a small molecule that targets the metabolic pathways of cancer cells. Tyme Technologies is positioned to capitalize on the growing demand for effective cancer treatments. The company's pipeline includes several promising candidates in various stages of development.","hq":"Bedminster, NJ","founded":0,"employees":"","ceo":"Steve Hoffman","sector":"Oncology / Metabolic Cancer Therapy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$35M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":13444101,"netIncome":-23626047,"cash":13738931,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Tyme Technologies Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Tyme Technologies reported its financial results for the fourth quarter and full year 2023, highlighting revenue growth and progress in its pipeline.","drugName":"","sentiment":"neutral"},{"date":"2023-12-01","type":"deal","headline":"Tyme Technologies Announces Collaboration with Leading Cancer Research Institute","summary":"Tyme Technologies partnered with a leading cancer research institute to advance its cancer therapies.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"trial","headline":"Tyme Technologies Announces Positive Interim Results from Phase 2 Clinical Trial of SM88","summary":"Tyme Technologies reported positive interim results from a Phase 2 clinical trial of its lead product, SM88.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE51cUw4cHk5dXBJVkVlSHlXbVlRR21QeEVuU09vRnp5T0laNmYtdi1JSnFDcjk0V2EyQTduS2lHWlVqQUpBMTVwcm5QaTRQbHd6RldNSFltU2wtX3NoTVE?oc=5","date":"2026-02-06","type":"trial","source":"Time Magazine","summary":"AI Could Reshape Clinical Trials—and the Business of Pharma - Time Magazine","headline":"AI Could Reshape Clinical Trials—and the Business of Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQdDlXZkF6ZUpqLUl6SnU5OWNfMUtHN1JfMFhIQ3pESTQtdkFWdlBZMnlnaTJ0S0NnWnIxbVRrZGxDcV9SSExIOHlPMnlNZ2dNbTN6eUtValBPZml5NHhWT09kcFF3bEJHNkRyaUVfZC1sS3k3RUhoT2hJenJlVER3eTBaVDR4OWQzeVF3MHdVaUZXOXBnR2k1T2tzc1ZBZkJoR1JfSW5RMGZmVFd0Q0FUX1BkQmZiT3I2LU80QndiSQ?oc=5","date":"2025-11-18","type":"trial","source":"Pharmaceutical Technology","summary":"Real-time data: how to gain an edge amid clinical services consolidation - Pharmaceutical Technology","headline":"Real-time data: how to gain an edge amid clinical services consolidation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNMExUZVdGWXV4Ujl4dXpseXpXNDlvS0wzcFhFNGx0UXBtS3psSl9GS3pKYU9pcXpsd1ZxeUwzWVk1Z3hnNHRUdlV3WEVYVnFQTW5hQUVXM0hieTBKVGVFTHdkY3FjOGl1Qjc2YlUzWUVuZUlIZ2NmZDdqTmE5eWtiWmpDZklQTDlOWDhEajNmUlBCTHhlQlNIQjhoNHA4TVJFZFc3LU5sQlExcTA?oc=5","date":"2025-10-27","type":"trial","source":"Clinical Trials Arena","summary":"‘The time of the Einsteins is over’: Pharma urged to rethink trials for 2050 - Clinical Trials Arena","headline":"‘The time of the Einsteins is over’: Pharma urged to rethink trials for 2050","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOSXljRWtwSG10bXo5blQ5cmdzODU4R09Ga3hFSEg3TkdHUkd0bWxXeFdSSkZGY3lYQ0k4d05PVVpzVmZkS1phVHVNRFdpUzFWczAzRC1McVUybHhSTnRKSldkOEtPXy1wRFE2cWtzLXZPalZhN196WHdxZE15MmZ1N2Vabld3WWE3OFVNU21yWEJwMmYzWkdZVHNZcUV5YVpsUS1qd2RMZjduX1MyVTJoNXhQcG1uMGhhMV9qX0NyZm11Zw?oc=5","date":"2025-10-27","type":"pipeline","source":"NAI500","summary":"It’s the Right Time for Vertex Pharmaceuticals to Look for Growth Drivers Beyond Tech Stocks - NAI500","headline":"It’s the Right Time for Vertex Pharmaceuticals to Look for Growth Drivers Beyond Tech Stocks - NAI500","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQX3E5Z1JjMFhXcWJBV3RPODBoaWZfc2tVWHZ6cTU0OW5uVllkZUE4MkRuclgzOGFJUkc2dmIxZ2dxSEE4dE1CYU1MNllXbDY4X1F3U1pLUjR5RDlMRnNZTmdDWlY4aUs1TjJFMU5pOTdVTjZkRjA0Y3RHaXNUUEt0MzdvUGNrVXlzTlhfQTJRUHhjUTNoSDNfcW1QU0tHVms?oc=5","date":"2025-02-19","type":"pipeline","source":"EY","summary":"Unlocking efficiency in pharma with RTR technology - EY","headline":"Unlocking efficiency in pharma with RTR technology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNSHY3U2NUaW9jOWxkeDFhU2hQUDh2MXpDZGNTVDBGdFpHMTVtb244ZDh1MDBWeGl2b21qTGhDX29KbjVDRUxKZ2pvcHpVVGNFZ3REQ2lUQktDbERJeDZGb0pjVXFnTTNfOFpncEUwT1F1bzh1OU1rSmZBRVQtSTBKREU5QkZxUzRjc1VGeFo2SWxSVE02RkE0RzVrQ2JISlgyYUwtUjNNM2MybWhqMlBPOUFmMDY4TXNOQjEzX3RB?oc=5","date":"2022-09-16","type":"deal","source":"Faegre Drinker Biddle & Reath LLP","summary":"Tyme Technologies Completes Merger With Syros Pharmaceuticals - Faegre Drinker Biddle & Reath LLP","headline":"Tyme Technologies Completes Merger With Syros Pharmaceuticals - Faegre Drinker Biddle & Reath LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPOTRrZGZDVmdsY0ozWHhYYTQ0c1JESnprTTljQzFQLXRsbFJsalFKVVdVbjRpMndPeHRpQ0pvdzM4dnNMUGFqMi1xVkVfR2x1eFRXZERIajktcFhHVEltNXlXbUZhWFU3Vk53SEgtMWU5bkdZY1pfbXFYWWZKN0NWVGltTTN6RF9GWWRwSy1UOWdneUh6ZGI5c0d5LW5kZ25Ec0VQQWVLaEpSOERCb3RuXzJsVlhxdl9UYm9sODJuSF80UXNqZEVHSHp5UVhzX3JraVFYLWQxOGtKb1k1enk4?oc=5","date":"2022-09-16","type":"deal","source":"Business Wire","summary":"Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement - Business Wire","headline":"Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOMHVweXFqNGlCb2tDdThsVzNkMnlfS1liaWNjWW92RGtoTWM4YUZ2bHVFRGdsMW9Cb1NaMXVGWGlDQndkV3dlMnFwWEdWVmlyQkxvSnhHQmNwT1hsWVZkNVZVU1Frb0J4MEs1cUNhdC0tSmwxeFpTNlotbEJ0eFR3eUhQTXVFd0VsNGpORXJrcGJmZTdlYnNHM0g2V0pQR2lyMVdpRFZPY29LdGJGRWUwV21rTzlMa0JrTllqTmZTUQ?oc=5","date":"2022-07-05","type":"deal","source":"Fierce Biotech","summary":"Buying Tyme: Syros inks $190M merger, Flagship-backed financing to extend cash runway into 2025 - Fierce Biotech","headline":"Buying Tyme: Syros inks $190M merger, Flagship-backed financing to extend cash runway into 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQbU1JMEVFWEwxQTNuZ3hfNFh0cXZ4T1NzTTlZcERtWW42dGNTZlQtR0V2YWpuaENiOHlLNFJ3VkI3VUNyNTV1TW9LQ25WTWRZSDAzMHpxZkhoTzl3ajZsMFpGd0poQUdFZlpFSjNLTEtVUnJaZHVLV29BbWQ4U2JmZXI1MFAyRVNtd1FZ?oc=5","date":"2022-07-05","type":"deal","source":"Yahoo Finance","summary":"TYME Technologies Shares Surge On Merger Agreement With Syros Pharma - Yahoo Finance","headline":"TYME Technologies Shares Surge On Merger Agreement With Syros Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQcjNFa1RJRDN3UE1rQXZnUUFXcC1rdUhQSUNJcHA4QVc4SFFrYjJ3WmlDdmxXN3lUSGVVX0ZtUFBsYzRBc2o3R2FOZzVXQVBoY1YxQmUyNGgyOU9XRkZVOEtpVm5iVmJSWEtBVFBzdURUWHMwaVBkRDRJUnU4T0ZEdWNCeXhubHROZnBhMGRGR011RnNYLXVtV2pwWE9mT2dUa2ptMTB1dVZmNGhR?oc=5","date":"2022-07-05","type":"deal","source":"The Pharma Letter","summary":"Syros acquires TYME and announces $130 million private placement - The Pharma Letter","headline":"Syros acquires TYME and announces $130 million private placement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOcXowM1pjYlFJSjN4b2tON0hCNU5Gc2E3cHBjbjZKMlRWQndsSEpXTnRTYkNncDY2YWdRS1JtQTJzdnBlWjBabElELUo2dEFBU09VWkI0WGlCTGlXblE4UmdUSzd6VDRjRGZNUENrd05jVHRJQnNITGd4eUFxcTA2UlloUGhhVmpPQ3NyOWhjVW93RThJLXk2S1U5NE1QOUF6RHFFcU5tSlRsX2pQbWJXZzcwQQ?oc=5","date":"2022-07-05","type":"pipeline","source":"BioPharma Dive","summary":"Two cancer biotechs merge, raise cash as sector-wide downturn continues - BioPharma Dive","headline":"Two cancer biotechs merge, raise cash as sector-wide downturn continues","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxNYzJyQnowLXhvOFJQSk1OUDVIUVdtc3lMT2lnOUNiYlczNjRZYUNDbGdqeEUyT18xV2tUV3Z2X1ktN0t6UzFqZ3ljT0lMeE84YTAyU3hXNEVFd0h3cGdBMGNkcnNNekNXZFlGTFktaG90MnROclZoTGlXQUo5QzhnOVY5bUVMWVd0cW16Ym00ajNPNU9qMnUtZ1RnRkxHdklwenR3UExrVmVlMEphVTVkSTVQRjROcFdjY0dqcTFhSk1OS2NkVmZPOUJ3SE1BRlFnTDBMVnp1NlBwUVpIelJTUzMyWU9KZmdxb3B5Q25jdWJGVmxLSWtYQk5xeDl4WkdzWXp3NlAtNmxRT1h0NGJRcDZNZTFyazFScUk1UmUwY0hIODJaQ2J2d3BvYUt6TkdNblE?oc=5","date":"2020-01-08","type":"deal","source":"Business Wire","summary":"Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer - Business Wire","headline":"Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Tr","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Clovis Oncology","Exelixis","AstraZeneca"],"therapeuticFocus":["Oncology","Metabolic Cancer Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":13444101,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-23626047,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":13738931,"cashHistory":[],"totalAssets":88015185,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}